169 related articles for article (PubMed ID: 31436301)
1. Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin‑resistant cell line to oxaliplatin by inhibiting excision repair cross‑complementing group 1 protein expression.
Li JM; Jiang GM; Zhao L; Yang F; Yuan WQ; Wang H; Luo YQ
Oncol Rep; 2019 Nov; 42(5):1725-1734. PubMed ID: 31436301
[TBL] [Abstract][Full Text] [Related]
2. The AKT/GSK3-Mediated Slug Expression Contributes to Oxaliplatin Resistance in Colorectal Cancer via Upregulation of ERCC1.
Wei W; Ma XD; Jiang GM; Shi B; Zhong W; Sun CL; Zhao L; Hou YJ; Wang H
Oncol Res; 2020 Sep; 28(4):423-438. PubMed ID: 32331534
[TBL] [Abstract][Full Text] [Related]
3. Annexin A3 depletion overcomes resistance to oxaliplatin in colorectal cancer via the MAPK signaling pathway.
Xu R; Yin J; Zhang Y; Zhang S
J Cell Biochem; 2019 Sep; 120(9):14585-14593. PubMed ID: 30998268
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of MEG3 sensitizes colorectal cancer cells to oxaliplatin through regulation of miR-141/PDCD4 axis.
Wang H; Li H; Zhang L; Yang D
Biomed Pharmacother; 2018 Oct; 106():1607-1615. PubMed ID: 30119236
[TBL] [Abstract][Full Text] [Related]
5. Astragaloside IV Induced miR-134 Expression Reduces EMT and Increases Chemotherapeutic Sensitivity by Suppressing CREB1 Signaling in Colorectal Cancer Cell Line SW-480.
Ye Q; Su L; Chen D; Zheng W; Liu Y
Cell Physiol Biochem; 2017; 43(4):1617-1626. PubMed ID: 29041002
[TBL] [Abstract][Full Text] [Related]
6. The Role of Cyanidin-3-
Kurter H; Basbinar Y; Ellidokuz H; Calibasi-Kocal G
Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004099
[TBL] [Abstract][Full Text] [Related]
7. β-Sitosterol Reverses Multidrug Resistance via BCRP Suppression by Inhibiting the p53-MDM2 Interaction in Colorectal Cancer.
Wang Z; Zhan Y; Xu J; Wang Y; Sun M; Chen J; Liang T; Wu L; Xu K
J Agric Food Chem; 2020 Mar; 68(12):3850-3858. PubMed ID: 32167760
[TBL] [Abstract][Full Text] [Related]
8. Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116.
Kukcinaviciute E; Jonusiene V; Sasnauskiene A; Dabkeviciene D; Eidenaite E; Laurinavicius A
J Cell Biochem; 2018 Jul; 119(7):5913-5920. PubMed ID: 29637602
[TBL] [Abstract][Full Text] [Related]
9. Silencing of E-cadherin expression leads to increased chemosensitivity to irinotecan and oxaliplatin in colorectal cancer cell lines.
Skarkova V; Skarka A; Manethova M; Stefanidi AA; Rudolf E
Hum Exp Toxicol; 2021 Dec; 40(12):2063-2073. PubMed ID: 34075792
[TBL] [Abstract][Full Text] [Related]
10. MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells.
Liang H; Xu Y; Zhang Q; Yang Y; Mou Y; Gao Y; Chen R; Chen C; Dai P
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):725-736. PubMed ID: 30861353
[TBL] [Abstract][Full Text] [Related]
11. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145.
Gao R; Fang C; Xu J; Tan H; Li P; Ma L
Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170
[TBL] [Abstract][Full Text] [Related]
12. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
[TBL] [Abstract][Full Text] [Related]
13. Role of Dicer in regulating oxaliplatin resistance of colon cancer cells.
Lai HH; Lin LJ; Hung LY; Chen PS
Biochem Biophys Res Commun; 2018 Nov; 506(1):87-93. PubMed ID: 30336979
[TBL] [Abstract][Full Text] [Related]
14. Prostaglandin F
Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ
World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995
[TBL] [Abstract][Full Text] [Related]
15. LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan.
Fakhr E; Zare F; Azadmanesh K; Teimoori-Toolabi L
Biomed Pharmacother; 2021 Nov; 143():112091. PubMed ID: 34474344
[TBL] [Abstract][Full Text] [Related]
16. Induction of epithelial-mesenchymal transition and down-regulation of miR-200c and miR-141 in oxaliplatin-resistant colorectal cancer cells.
Tanaka S; Hosokawa M; Yonezawa T; Hayashi W; Ueda K; Iwakawa S
Biol Pharm Bull; 2015; 38(3):435-40. PubMed ID: 25757925
[TBL] [Abstract][Full Text] [Related]
17. PDGF-D promotes cell growth, aggressiveness, angiogenesis and EMT transformation of colorectal cancer by activation of Notch1/Twist1 pathway.
Chen J; Yuan W; Wu L; Tang Q; Xia Q; Ji J; Liu Z; Ma Z; Zhou Z; Cheng Y; Shu X
Oncotarget; 2017 Feb; 8(6):9961-9973. PubMed ID: 28035069
[TBL] [Abstract][Full Text] [Related]
18. Luteolin inhibits colorectal cancer cell epithelial-to-mesenchymal transition by suppressing CREB1 expression revealed by comparative proteomics study.
Liu Y; Lang T; Jin B; Chen F; Zhang Y; Beuerman RW; Zhou L; Zhang Z
J Proteomics; 2017 May; 161():1-10. PubMed ID: 28391045
[TBL] [Abstract][Full Text] [Related]
19. P53‑microRNA interactions regulate the response of colorectal tumor cells to oxaliplatin under normoxic and hypoxic conditions.
Zhang J; Li C; Sun L; Sun D; Zhao T
Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37921068
[TBL] [Abstract][Full Text] [Related]
20. The role of hERG1 ion channels in epithelial-mesenchymal transition and the capacity of riluzole to reduce cisplatin resistance in colorectal cancer cells.
Fortunato A
Cell Oncol (Dordr); 2017 Aug; 40(4):367-378. PubMed ID: 28593575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
